MicroPort NeuroTech Limited
HKSE: 2172.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Zhiyong Xie
- Employees
- 527
- Headquarters
- Shanghai, China
- IPO year
- 2022
- Market cap
- HK$6.1B
- Website
- https://www.medneurotech.com
Loading 2172…
Loading profile data…Frequently asked questions about 2172
What does MicroPort NeuroTech Limited (2172.HK) do?
MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and...
Where does 2172.HK trade?
MicroPort NeuroTech Limited (2172.HK) trades on the Hong Kong Stock Exchange.
What sector is 2172.HK in?
MicroPort NeuroTech Limited (2172.HK) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of MicroPort NeuroTech Limited?
Zhiyong Xie is the chief executive officer of MicroPort NeuroTech Limited (2172.HK).
Where is MicroPort NeuroTech Limited headquartered?
MicroPort NeuroTech Limited is headquartered in China.
Does 2172.HK pay a dividend?
Yes — MicroPort NeuroTech Limited (2172.HK) paid a trailing twelve-month dividend of HKD 0.16 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 2172.HK go public?
MicroPort NeuroTech Limited (2172.HK) completed its initial public offering in 2022.